

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | | |
|----|--|
| 1. | Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|----|--|

No equality issues were identified at scoping.
--

- | | |
|----|---|
| 2. | Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|----|---|

Patient organisation submissions noted that hepatocellular carcinoma (HCC) disproportionately affects those from a poor socioeconomic background. Many people with HCC come from disadvantaged backgrounds and have complex lives. There are strong links with deprivation (including homelessness, heavy alcohol and drug use, obesity). This issue relates to prevalence and could not be addressed via an appraisal.

- | | |
|----|---|
| 3. | Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|----|---|

No

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma

4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No	

5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No	

6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No	

7.	Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?
No	

Approved by Principal Technical Adviser (name): Elizabeth Bell

Date: 21/05/2025

Final draft guidance

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

5. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes, the committee's considerations of equalities issues are described in section 3.17 of the final draft guidance.

Approved by Principal Technical Adviser (Elizabeth Bell): Elizabeth Bell

Date: 12/06/2025